AML Clinical Trials 2023

What are the top hospitals conducting aml research?

Houston's MD Anderson Cancer Center takes the lead in clinical trials for acute myeloid leukemia (AML), with an impressive 13 active trials and a total of 92 trials conducted thus far. This renowned institution has been at the forefront of AML research since recording its first trial in 2001, showcasing unwavering dedication to finding new treatments and improving patient outcomes. Meanwhile, Massachusetts General Hospital in Boston is also making substantial contributions to AML research, actively conducting 10 trials and having completed 70 studies since their initial trial in 2003.

Notably, another Texas-based hospital—MD Anderson Cancer Center—shares the same name but operates independently from its Houston counterpart. This M D Anderson facility boasts an equally impressive track record with AML research: they currently have ten ongoing clinical trials and have participated in a remarkable total of 93 studies since initiating their inaugural trial back in1999.

Further adding to this list is City of Hope located in Duarte, Californiaoid leukemia (AML), with an impressive 13 active trials and a total of 92 trials conducted thus far. This renowned institution has been at the forefront of AML research since recording its first trial in 2001, showcasing unwavering dedication to finding new treatments and improving patient outcomes. Meanwhile, Massachusetts General Hospital in Boston is also making substantial contributions to AML research, actively conducting 10 trials and having completed 70 studies since their initial trial in 2003.

Notably, another Texas-based hospital—MD Anderson Cancer Center—shares the same name but operates independently from its Houston counterpart. This M D Anderson facility boasts an equally impressive track record with AML research: they currently have ten ongoing clinical trials and have participated in a remarkable total of 93 studies since initiating their inaugural trial back in1999.

Further adding to this list is City of Hope located in Duarte, California. Although it may have fewer active AML trials compared to some others on this list—with nine currently underway—it still holds significant importance within the field as it has contributed to advancing knowledge through a notable number of previous thirty-eight investigations that began all the way backin2004.

Lastly, Roswell Park Cancer Institute situated in Buffalo deserves recognition for its extensive efforts devoted to combating AML. With nine ongoing clinical trials tackling this challenging disease and an astonishing tally of107 previously completed studies dating backto1997,it remains a pivotal institution dedicated to unraveling mysteries surrounding effective treatment options for patients battling AML.

These hospitals exemplify dedication towards understanding and treating acute myeloid leukemia while driving forward medical innovation. Their collective efforts bring hope not only those directly impacted by this aggressive blood cancer but also encourage progress that ultimately benefits individuals worldwide facing similar challenges.

Which are the best cities for aml clinical trials?

When it comes to AML clinical trials, several cities stand out as top destinations for research. Boston, Massachusetts leads the way with 49 active trials investigating treatments like AG-120, CC-90009, and cytarabine. New York City closely follows with 47 ongoing studies focusing on CC-486, Cytarabine, and Oral Azacitidine. Houston, Texas and Chicago, Illinois tie with 46 active trials each exploring treatments such as Venetoclax and AG-120. Lastly, Saint Louis in Missouri offers 24 active trials studying medications like CC-90009 and Cytarabine. These cities provide individuals with access to cutting-edge AML clinical trials that hold promise for improved treatment options and better outcomes.

Which are the top treatments for aml being explored in clinical trials?

Clinical trials are paving the way for potential breakthroughs in treating acute myeloid leukemia (AML). Among the top contenders, venetoclax emerges as a frontrunner with eight active trials and an impressive track record of 130 all-time AML trials since its debut in 2014. Cytarabine follows closely, participating in five ongoing studies and boasting a remarkable 246 all-time AML trials since its introduction in 2001. Another promising treatment is liposome-encapsulated Daunorubicin-Cytarabine, currently involved in five active trials and showing promise since it was listed in 2015. Pevonedistat, with three active trials, and CPX-351, with two active trials round out this select group of groundbreaking therapies being explored to combat AML. These ongoing efforts bring hope to those affected by this challenging disease.

What are the most recent clinical trials for aml?

Exciting advancements are being made in the field of acute myeloid leukemia (AML) with recent clinical trials offering new possibilities for treatment. One notable trial is investigating the effectiveness of Meropenem as a potential therapy for AML patients, providing insights into its efficacy and safety. Additionally, another trial focuses on determining the optimal dosage level in Phase 1 patients receiving novel treatments for AML. Moreover, Regimen A: TBI/Thiotepa/Cyclophosphamide explores a combination approach to combat this aggressive form of leukemia. These ongoing studies offer hope and promise to those affected by AML, pushing forward our understanding and options for managing this challenging disease.

What aml clinical trials were recently completed?

Recently completed clinical trials in the field of acute myeloid leukemia (AML) include various innovative investigations. In June 2021, AbbVie concluded a trial examining Lemzoparlimab as a potential treatment option. Additionally, Pfizer's Azacitidine trial reached completion in May 2021. Last year, Bhavana Bhatnagar successfully wrapped up a Dubermatinib study in November 2020, while Rutgers, The State University of New Jerseyd leukemia (AML) include various innovative investigations. In June 2021, AbbVie concluded a trial examining Lemzoparlimab as a potential treatment option. Additionally, Pfizer's Azacitidine trial reached completion in May 2021. Last year, Bhavana Bhatnagar successfully wrapped up a Dubermatinib study in November 2020, while Rutgers, The State University of New Jersey finalized their Salsalate trial in October of the same year. These recent advancements highlight ongoing efforts to advance AML treatments and offer hope for patients grappling with this challenging disease.